Abstract | CONTEXT:
Hemoglobin-based blood substitutes (HBBSs) are infusible oxygen-carrying liquids that have long shelf lives, have no need for refrigeration or cross-matching, and are ideal for treating hemorrhagic shock in remote settings. Some trials of HBBSs during the last decade have reported increased risks without clinical benefit. OBJECTIVE: To assess the safety of HBBSs in surgical, stroke, and trauma patients. DATA SOURCES: PubMed, EMBASE, and Cochrane Library searches for articles using hemoglobin and blood substitutes from 1980 through March 25, 2008; reviews of Food and Drug Administration (FDA) advisory committee meeting materials; and Internet searches for company press releases. STUDY SELECTION: Randomized controlled trials including patients aged 19 years and older receiving HBBSs therapeutically. The database searches yielded 70 trials of which 13 met these criteria; in addition, data from 2 other trials were reported in 2 press releases, and additional data were included in 1 relevant FDA review. DATA EXTRACTION: RESULTS: Sixteen trials involving 5 different products and 3711 patients in varied patient populations were identified. A test for heterogeneity of the results of these trials was not significant for either mortality or MI (for both, I2 = 0%, P > or = .60), and data were combined using a fixed-effects model. Overall, there was a statistically significant increase in the risk of death (164 deaths in the HBBS-treated groups and 123 deaths in the control groups; relative risk [RR], 1.30; 95% confidence interval [CI], 1.05-1.61) and risk of MI (59 MIs in the HBBS-treated groups and 16 MIs in the control groups; RR, 2.71; 95% CI, 1.67-4.40) with these HBBSs. Subgroup analysis of these trials indicated the increased risk was not restricted to a particular HBBS or clinical indication. CONCLUSION: Based on the available data, use of HBBSs is associated with a significantly increased risk of death and MI.
|
Authors | Charles Natanson, Steven J Kern, Peter Lurie, Steven M Banks, Sidney M Wolfe |
Journal | JAMA
(JAMA)
Vol. 299
Issue 19
Pg. 2304-12
(May 21 2008)
ISSN: 1538-3598 [Electronic] United States |
PMID | 18443023
(Publication Type: Journal Article, Meta-Analysis, Research Support, N.I.H., Extramural)
|
Chemical References |
- Blood Substitutes
- Hemoglobins
- O-raffinose cross-linked human hemoglobin
- PolyHeme
- HBOC 201
- Raffinose
|
Topics |
- Blood Substitutes
(adverse effects)
- Hemoglobins
(adverse effects)
- Humans
- Mortality
- Myocardial Infarction
(epidemiology)
- Raffinose
(adverse effects, analogs & derivatives)
- Risk
|